Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast agent ...
Bayer announced today 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its MEDRAD ® Centargo CT Injection System, an innovative multi-patient injector that drives workflow ...
LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global contrast injectors market since 2015 and the market is poised to grow by USD 613.47 million during 2020-2024, progressing at a CAGR of ...
(2). Scope of Work: The Contractor shall provide all resources necessary to accomplish the deliverables described in this statement of work (SOW), except as may otherwise be specified. (3). Background ...
The "Contrast Media Injectors Market By Product (Injector Systems, Consumables), By Type (Single Head, Dual-Head, Syringeless Injectors), By Application, By End-use, And Segment Forecasts, 2014 - 2025 ...
LONDON, Feb. 22, 2018 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/5291777 The global contrast media injectors market is expected to ...
Centargo compatible with Ultravist® (iopromide), Isovue® (iopamidol), Optiray® (ioversol), Omnipaque™ (iohexol) and now, Visipaque™ (iodixanol) Follows recent FDA clearance to expand the use of ...
Follows recent FDA clearance to expand the use of compatible contrast agent presentations, adding single-dose vials in addition to Imaging Bulk Package presentations Radiology suites now have the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback